← ACADIA PHARMACEUTICALS INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying Value | $163.6m | $69.4m | $134.8m | $189.7m | $326.0m | $147.4m | $114.8m | $188.7m | $319.6m | $177.7m | |
| Prepaid Expense and Other Assets, Current | $7.5m | — | — | — | — | — | — | — | — | — | |
| Inventory, Net | $4.2m | $5.2m | $4.1m | $6.3m | $9.7m | $14.1m | $11.6m | $40.4m | $91.7m | $111.4m | |
| Assets, Current | $547.9m | $373.5m | $526.1m | $760.2m | $717.6m | $617.8m | $507.9m | $616.1m | $938.3m | $1.1b | |
| Property, Plant and Equipment, Net | $3.1m | $2.7m | $3.3m | $3.2m | $9.2m | $8.0m | $6.0m | $4.6m | $4.2m | $7.5m | |
| Intangible Assets, Net (Excluding Goodwill) | $7.0m | $5.5m | $4.1m | $2.6m | $1.1m | $0 | — | — | — | — | |
| Operating Lease, Right-of-Use Asset | — | — | $0 | $9.5m | $47.3m | $58.3m | $55.6m | $51.9m | $46.6m | $47.4m | |
| Other Assets, Noncurrent | $785k | $354k | $1.9m | $2.9m | $1.7m | $4.0m | $7.6m | $476k | $359k | $3.9m | |
| Additional Financial Items | |||||||||||
| Accounts Receivable, after Allowance for Credit Loss, Current | $5.9m | $17.3m | $26.1m | $35.8m | $48.2m | $64.4m | $62.2m | $98.3m | $98.7m | $121.5m | |
| Accrued Liabilities, Current | $36.0m | $40.2m | $56.4m | $67.6m | $97.5m | $89.2m | $112.9m | $236.7m | $378.7m | $266.2m | |
| Assets | $561.2m | $384.5m | $540.2m | $783.2m | $782.6m | $700.1m | $587.8m | $749.0m | $1.2b | $1.6b | |
| LIABILITIES AND EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Operating Lease, Liability, Current | — | — | — | $3.4m | $5.1m | $8.3m | $9.3m | $9.4m | $10.0m | $11.6m | |
| Accounts Payable, Current | $3.9m | $8.8m | $3.2m | $7.2m | $8.5m | $6.9m | $12.7m | $17.5m | $16.2m | $10.9m | |
| Operating Lease, Liability, Noncurrent | — | — | — | $6.4m | $44.5m | $56.1m | $52.7m | $47.8m | $42.0m | $40.6m | |
| Deferred Revenue, Current | $2.6m | — | — | — | — | — | — | — | — | — | |
| Liabilities, Current | $42.6m | $49.0m | $59.6m | $74.8m | $106.0m | $96.1m | $125.6m | $254.3m | $394.9m | $277.1m | |
| Deferred Income Tax Liabilities, Net | — | — | — | $2.3m | $12.5m | $14.1m | $13.2m | $12.4m | $11.4m | $11.2m | |
| Other Liabilities, Noncurrent | — | — | — | $2.9m | $5.2m | $7.0m | $9.1m | $15.1m | $18.1m | $19.1m | |
| Liabilities | $42.7m | $49.2m | $61.1m | $84.0m | $155.6m | $159.2m | $187.4m | $317.2m | $455.0m | $336.8m | |
| Stockholders’ equity: | |||||||||||
| Preferred Stock, Value, Issued | — | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | |
| Common Stock, Value, Issued | $12k | $12k | $14k | $15k | $16k | $16k | $16k | $16k | $16k | $16k | |
| Additional Paid in Capital | $1.5b | $1.6b | $1.9b | $2.4b | $2.6b | $2.7b | $2.8b | $2.9b | $2.9b | $3.0b | |
| Retained Earnings (Accumulated Deficit) | ($934.0m) | ($1.2b) | ($1.5b) | ($1.7b) | ($2.0b) | ($2.2b) | ($2.4b) | ($2.4b) | ($2.2b) | ($1.8b) | |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | $106k | ($399k) | ($372k) | $297k | $36k | ($192k) | ($975k) | $24k | $292k | $1.4m | |
| Additional Paid in Capital, Common Stock | — | $1.6b | $1.9b | $2.4b | $2.6b | $2.7b | $2.8b | $2.9b | $2.9b | $3.0b | |
| Stockholders' Equity Attributable to Parent | $518.4m | $335.3m | $479.1m | $699.1m | $627.0m | $540.9m | $400.4m | $431.8m | $732.8m | $1.2b | |
| Liabilities and Equity | $561.2m | $384.5m | $540.2m | $783.2m | $782.6m | $700.1m | $587.8m | $749.0m | $1.2b | $1.6b |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.